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With support from patient associations, political frame-
works for rare diseases have been established through-
out the world albeit with varying definitions for rare
diseases.
In the USA, the National Organization for Rare Disor-
ders was instrumental in passing the 1983 Orphan Drug
Act and the 2002 Rare Disease Act, which includes medi-
cal devices and dietary products as orphan products. In
2011, the House passed bills supporting research for
undiagnosed diseases and preserving regulatory fee excep-
tions for orphan drugs.
In 2012, the Canadian government awarded five-year
rare disease research grants. With advocacy from the
Canadian Organization for Rare Disorders, Health Canada
concluded consultations on an orphan drug regulatory fra-
mework. Several provinces have implemented orphan drug
access programs and expanded newborn screening.
In Argentina, the Geiser Foundation led advocacy result-
ing in the 2011 Rare Disease Law, obliging health and
social systems to provide assistance. A central committee,
including patients, will coordinate activities like neonatal
screening and patient registries. In 2010, Colombia passed
the Orphan Disease Law and hosted the 2nd National
Forum of Orphan Diseases. In 2011, Peru passed legislation
promoting treatment and a national strategy including
diagnosis, surveillance, prevention, care, and rehabilitation.
Through the 1972 Medical Care Program for Specific
Diseases, Japan provides medical cost subsidy to patients
affected by “56 rare and intractable diseases.” The 1993
Orphan Drug Law supports research and development.
In 2008, Supporting Organizations for Patients with Rare
Diseases was formed.
Since 1991, Singapore’s Orphan Drugs Policy allows
patients with life-threatening and severely debilitating
diseases with no other treatment options to access
approved drugs prescribed by their practitioner.
The Taiwan Foundation for Rare Disorders helped
secure the Rare Disease and Orphan Drugs Act in 2000.
Diseases affecting fewer than 1 in 10,000 that are offi-
cially recognized are eligible for medical coverage. In
Korea, the Orphan Drug Centre supplies medicines for
diseases affecting fewer than 1 in 20,000. The Genetics
and Rare Disease Centre supports national reference
centres and research.
In China, in 2011, medical professionals called for leg-
islation to support healthcare, research, orphan drug
development, and epidemiological studies for diseases
affecting fewer than 1 in 10,000.
Australia’s 1987 Orphan Drugs Policy makes available
rare disease drugs, based on US regulatory information.
In 2010, consultation for a national strategy was posted
online. In 2012, Rare Voices Australia was formed.
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